Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 6/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.45 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.45 |
| ▸ | GALR3 | O60755 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910739 | 0.78 | CHRM1 (0.45) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL1025534 | 0.76 | CHRM5 (0.44) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL3118709 | 0.75 | CHRM5 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL3840099 | 0.75 | CHRM5 (0.44) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL20531615 | 0.74 | CHRM5 (0.42) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL1003888 | 0.72 | CHRM5 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL28497595 | 0.72 | CHRM5 (0.41) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL28506563 | 0.70 | CYP2C19 (0.41) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL27883926 | 0.70 | CHRM5 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL28464604 | 0.70 | CHRM5 (0.43) | CHRM5CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9375445-B2 | Heparin prodrugs and drug delivery stents formed therefrom | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9364498-B2 | Heparin prodrugs and drug delivery stents formed therefrom | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20090258047-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258029-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258054-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTTE CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258055-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTTE CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7563780-B1 | Heparin prodrugs and drug delivery stents formed therefrom | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7396541-B2 | Heparin prodrugs and drug delivery stents formed therefrom | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20060014720-A1 | Heparin prodrugs and drug delivery stents formed therefrom | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014720-A1 | Heparin prodrugs and drug delivery stents formed therefrom | PLAUR, HDGF, AXL | CHRM5 3411/4885CHRM1 3145/4885CHRM3 3313/4885 |
| US-20090258054-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | PLAUR, HDGF, AXL | CHRM5 3411/4885CHRM1 3145/4885CHRM3 3313/4885 |
| US-20090258055-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | PLAUR, HDGF, AXL | CHRM5 3411/4885CHRM1 3145/4885CHRM3 3313/4885 |
| US-20090258029-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | PLAUR, HDGF, AXL | CHRM5 3411/4885CHRM1 3145/4885CHRM3 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.